OncoSec Medical Incorporated (ONCS) Stock Price Up 9%
OncoSec Medical Incorporated (NASDAQ:ONCS) rose 9% during trading on Wednesday . The company traded as high as $1.12 and last traded at $1.09. Approximately 1,330,679 shares traded hands during trading, an increase of 976% from the average daily volume of 123,695 shares. The stock had previously closed at $1.00.
ONCS has been the subject of a number of research reports. Noble Financial restated a “buy” rating on shares of OncoSec Medical in a research report on Wednesday, June 14th. Dawson James restated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th. ValuEngine upgraded OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Finally, Maxim Group restated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $5.33.
The stock’s 50 day moving average is $0.99 and its 200 day moving average is $1.07. The stock’s market capitalization is $23.07 million.
COPYRIGHT VIOLATION WARNING: “OncoSec Medical Incorporated (ONCS) Stock Price Up 9%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/11/oncosec-medical-incorporated-oncs-stock-price-up-9.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.